Does TPE work? Based on the best direct human evidence we have right now, yes, therapeutic plasma exchange appears to improve biological age biomarkers under controlled study conditions. In the May 2025 Aging Cell trial, TPE plus IVIG reduced biological age by an average of 2.61 years, while TPE alone reduced it by 1.32 years. That matters. But the study did not prove longer lifespan, lower disease risk, or guaranteed benefit for every patient. It measured biomarker change, not decades of clinical outcomes. Strong evidence, still early.
If you are searching for the Buck Institute plasma exchange study or the TPE clinical trial 2025, this is the paper people mean: Fuentealba et al., published in Aging Cell in May 2025. The trial was conducted by researchers affiliated with the Buck Institute for Research on Aging and Circulate Health. It enrolled 42 healthy adults over age 50 and used a randomized, placebo-controlled design (which is a much higher bar than the average longevity headline).
Participants were assigned to treatment groups that included therapeutic plasma exchange alone, therapeutic plasma exchange with intravenous immunoglobulin, or control conditions. The investigators then tracked how those interventions changed a set of biological age biomarkers across multiple systems. The result that got the most attention was simple enough to repeat in one line: TPE plus IVIG produced an average biological age reduction of 2.61 years, and TPE alone produced an average reduction of 1.32 years.
What exactly were they measuring? Not wrinkles. Not VO2 max. Not who lived longer. They measured epigenetic clocks, DNA methylation-based biomarkers that estimate biological age, alongside broader multi-omics markers and physical measures. In practical terms, the researchers were asking whether the molecular pattern in a participant's blood looked older or younger after treatment.
Two details matter because they keep the conversation honest. First, the effect appeared to be strongest in the first three sessions, with diminishing returns after that. Second, 2 of the 42 participants discontinued the study. So this was not magic, and it was not a frictionless wellness add-on. It was a real clinical protocol with measurable effects, measurable limits, and the kind of signal that deserves serious follow-up.
For a field crowded with vague claims, that is a meaningful step up in rigor. And it is why this paper changed the conversation around TPE biological age reduction from theory to data.
Epigenetic clocks sound more mysterious than they are. As we age, chemical tags called methyl groups accumulate and shift across specific sites on our DNA. Those patterns change in fairly predictable ways over time. Researchers can examine thousands of those sites at once and use them to generate a biological age estimate (not your birthday age, but the age your molecular profile resembles).
That is why epigenetic clocks are widely used in aging research. They give scientists a way to detect change on a biologically meaningful timescale without waiting 20 years to see who develops disease first. But there is an important boundary here. These clocks are biomarkers, not final clinical outcomes.
Here is the plain-English distinction: saying your biological age markers improved is not the same as saying you will live longer. It is closer to saying that your lab profile moved in a direction researchers associate with younger biology. Useful? Yes. Definitive? No. But that distinction matters, especially in longevity medicine, where marketing often outruns the evidence.
At the same time, biomarkers are not trivial just because they are not destiny. In cardiovascular medicine, lipid markers matter. In diabetes care, A1c matters. In aging science, epigenetic clocks have become one of the main tools for quantifying whether an intervention is moving the biology in the direction researchers want to see. That does not make them a stand-alone clinical diagnostic (they are not), but it does make them worth taking seriously.
The short answer is that the 2.61-year result is real under the conditions of the study. It means that, on average, the participants who received TPE plus IVIG showed a measurable improvement in biological age biomarkers. TPE alone also moved those markers, just less dramatically. That is the signal.
The part that deserves equal airtime is the qualifier. It does not mean every person who gets TPE will shave 2.61 years off their biological age. That number is an average. Some participants likely responded more than that, some less, and some may have shown little change. That is how good evidence is supposed to work. It narrows uncertainty without overpromising what one trial can prove.
For patients, that means two things. First, TPE should be understood as a measured intervention, not a luxury add-on. Second, your own response should be tracked instead of assumed. If a clinic quotes the 2.61-year number but does not measure what happens in your case, they are borrowing the study's credibility without doing the study's work.
"Science is showing that while chronological aging is inevitable, biological aging is malleable. There's a part of it that you can fight."
- Dr. Eric Verdin, MD
That quote resonates because it gets the tone right. Biological aging may be modifiable. It is not fully controllable. For direct human longevity evidence, this trial is about as rigorous as the field currently gets. And for TPE specifically, it is the strongest controlled human study to date. That is why patients who want an honest answer to does TPE work should know this paper, not just the marketing summary.
If you want the practical version, start with our therapeutic plasma exchange page, then compare it with our breakdown of TPE cost in NYC and our guide to TPE vs other longevity treatments. The point is not to push everyone into the same protocol. It is to show where the evidence is strongest, where it is thinner, and who may actually be a fit.
The 2025 paper did not appear out of nowhere. The key earlier human paper was Kim et al. 2022 in GeroScience, titled Old plasma dilution reduces human biological age. That study helped establish the biological mechanism behind plasma exchange, namely the idea that removing and replacing age-altered plasma can shift inflammatory and regenerative signaling in a younger direction.
The 2022 work looked at changes in the systemic proteome, immune markers, DNA damage, senescence markers, and other hallmarks associated with aging. It gave the field a plausible mechanistic backbone. In other words, it helped answer why might plasma exchange affect aging biology at all? That matters because you want more than a before-and-after anecdote in a space like this.
But the 2022 study was not the final word. It was earlier-stage clinical evidence, with far less protection against bias than a proper randomized controlled design. The 2025 Fuentealba trial built on that foundation by asking the next, more useful question: if you take the idea into a more rigorous trial structure, do you still see the signal? The answer was yes.
That progression is how good medicine is supposed to work (mechanism first, then more disciplined testing). First you establish that the biology is plausible. Then you ask whether the effect survives tighter study design. TPE now has both pieces. Not perfect certainty, but a much better evidence stack than most interventions sold under the longevity label.
This is the section many clinics skip. We do not skip it, because the caveats are where patient trust is either earned or lost.
That does not weaken the study. It places it correctly. Good evidence should narrow uncertainty, not pretend to erase it. And in longevity medicine, the honest position is often: promising, measurable, not yet definitive.
Liondale's response to that uncertainty is practical. We track individual biomarker response before and after treatment and adjust the protocol accordingly. If your markers are moving in the right direction, good. If they are not, we want to know that early, not six months later after repeating a template plan that may not be doing much for you. That is how a physician-led practice should use emerging evidence, carefully and case by case.
Liondale Medical is a Circulate Health partner, which matters because Circulate developed and studied the protocol behind the 2025 trial. In practice, that means we use a Circulate-informed TPE model with pre- and post-treatment lab tracking, and a patient-specific evaluation of whether IVIG belongs in the protocol. It does not get added automatically just because the headline number is larger.
Every session is treated as a measured intervention. We obtain pre-treatment and post-treatment lab panels, review inflammatory and metabolic markers, and where appropriate evaluate biological age biomarkers. Dr. Bissoon personally reviews those results and adjusts the plan based on what your data shows. Short version: the protocol is standardized where it should be standardized, and individualized where it should be individualized.
That distinction matters for a premium New York practice. Many of our patients are already doing the basics well, sleep, exercise, nutrition, metabolic screening. They are not looking for hype. They want to know whether a treatment changes anything objective. They also want a physician willing to say when the answer is not yet clear. That is the standard here.
"Watching all my bloodwork numbers move into or towards the green gives me a lot of confidence in what I'm doing with TPE."
- Kevin MacDonald
That is a patient statement, not a clinical endpoint. But it captures something important. Patients feel more confident when treatment is tracked, interpreted, and adjusted rather than sold as an article of faith. If you are considering TPE at Liondale, that is the framework you should expect.
TPE has been shown to reduce biological age biomarkers in human studies, including an average 2.61-year reduction in the 2025 Aging Cell trial when TPE was combined with IVIG. That is not the same as proving longer lifespan or permanent age reversal (important distinction), but it is legitimate evidence that the biology moved in a younger direction.
They are among the most widely used biomarkers in aging research because DNA methylation patterns change predictably with age. They are useful for measuring biological response to an intervention, but they are not yet a stand-alone clinical diagnostic and should not be confused with hard outcomes like disease events or survival.
The 2022 GeroScience paper established much of the biological rationale by showing that plasma dilution could shift age-related markers in a younger direction. The 2025 trial improved on that by using a randomized, placebo-controlled design, which makes the result more persuasive and more clinically relevant.
No. The 2.61-year and 1.32-year figures are averages, not guarantees for every person. Individual response varied, and the strongest improvements were seen in participants with poorer baseline health markers (which is often true in medicine more broadly).
The study included repeated treatment sessions, and the strongest effects were reported after the first three sessions, with diminishing returns after that. That suggests more treatment is not always proportionally better, which is one reason protocol timing matters.
The Buck Institute for Research on Aging is a leading independent biomedical research institute focused on aging science. Its involvement gives the 2025 TPE study more scientific credibility than the average private-clinic case series or marketing claim.
Yes. Liondale is a Circulate Health partner and uses a Circulate-informed TPE model with pre- and post-treatment lab tracking. IVIG is evaluated case by case, not applied as a default, because patient selection still matters.
We do not assume success. We measure your response with pre-treatment and post-treatment labs, then adjust the protocol based on the data. If your markers are not moving in the expected direction, that becomes a clinical decision point, not something we ignore.
This article was written and reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan. Liondale Medical is a Circulate Health partner.
This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.
